We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I
Read MoreHide Full Article
Eli Lilly & Company’s (LLY - Free Report) partner China-based Junshi Biosciences has dosed the first healthy volunteer in phase I study on JS016, their antibody candidate for treating COVID-19.
Lilly signed the deal with Junshi last month to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19. Junshi has dosed the patient in a phase I study in China, while Lilly will soon begin its phase I study in United States.
The phase I studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with coronavirus.
While Junshi Biosciences has rights to products under the deal in Greater China, Lilly has exclusive development, manufacturing and distribution rights of products in the rest of the world. Lilly will study JS016 both as a monotherapy as well as in combination with other antibody treatments including LY-CoV555, its another potential COVID-19 antibody therapy candidate.
Lilly’s shares have risen 13.6% this year so far against a decrease of 1.3% for the industry.
Last week, Lilly announced initiation of a phase I study on LY-CoV555, its lead antibody therapy candidate in collaboration with private biotech, AbCellera. Lilly signed the deal with AbCellera in March to create antibody therapies to treat and prevent COVID-19.
LY-CoV555 is the first candidate to emerge from the collaboration and Lilly claims it has the potential for both prevention and treatment of COVID-19. The phase I study on LY-CoV555 will evaluate its safety and tolerability in patients hospitalized with COVID-19. Results from the study are expected in June, following which it plans to initiate broader efficacy studies. Lilly is also beginning large-scale manufacturing of this potential therapy simultaneously with its R&D efforts. Lilly plans to study LY-CoV555 in more vulnerable population if results of the phase I study are positive.
Lilly is making rigorous efforts to make medicines/antibodies to treat COVID-19. Lilly’s JAK inhibitor, Olumiant (baricitinib) is being evaluated as a potential treatment for hospitalized patients diagnosed with COVID-19 in a study conducted by NIAID. Lilly is also evaluating its monoclonal antibody candidate that inhibits Angiopoietin 2 (Ang2), LY3127804 in a phase II study in pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome (ARDS). Ang2 is found in high levels in ARDS patients. The study will test if LY3127804 can inhibit the effects of Ang2 and reduce the progression to ARDS or the need for mechanical ventilation in COVID-19 patients
Several other companies are also working on developing new antibodies to combat the disease.
Vir Biotechnology’s (VIR - Free Report) investigational monoclonal antibodies, VIR-7831 and VIR-7832 are expected to directly go to phase II clinical studies sometime in 2020. Regeneron (REGN - Free Report) is developing REGN-COV2, a novel investigational antibody "cocktail" treatment designed to prevent and treat the SARS-CoV-2 virus. Clinical studies are expected to begin this month.
Other than Lilly, larger companies like Pfizer (PFE - Free Report) , Biogen, Glaxo and Amgen also have signed collaborations with smaller biotechs to co-develop antibody therapies/medicines to treat COVID-19.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I
Eli Lilly & Company’s (LLY - Free Report) partner China-based Junshi Biosciences has dosed the first healthy volunteer in phase I study on JS016, their antibody candidate for treating COVID-19.
Lilly signed the deal with Junshi last month to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19. Junshi has dosed the patient in a phase I study in China, while Lilly will soon begin its phase I study in United States.
The phase I studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with coronavirus.
While Junshi Biosciences has rights to products under the deal in Greater China, Lilly has exclusive development, manufacturing and distribution rights of products in the rest of the world. Lilly will study JS016 both as a monotherapy as well as in combination with other antibody treatments including LY-CoV555, its another potential COVID-19 antibody therapy candidate.
Lilly’s shares have risen 13.6% this year so far against a decrease of 1.3% for the industry.
Last week, Lilly announced initiation of a phase I study on LY-CoV555, its lead antibody therapy candidate in collaboration with private biotech, AbCellera. Lilly signed the deal with AbCellera in March to create antibody therapies to treat and prevent COVID-19.
LY-CoV555 is the first candidate to emerge from the collaboration and Lilly claims it has the potential for both prevention and treatment of COVID-19. The phase I study on LY-CoV555 will evaluate its safety and tolerability in patients hospitalized with COVID-19. Results from the study are expected in June, following which it plans to initiate broader efficacy studies. Lilly is also beginning large-scale manufacturing of this potential therapy simultaneously with its R&D efforts. Lilly plans to study LY-CoV555 in more vulnerable population if results of the phase I study are positive.
Lilly is making rigorous efforts to make medicines/antibodies to treat COVID-19. Lilly’s JAK inhibitor, Olumiant (baricitinib) is being evaluated as a potential treatment for hospitalized patients diagnosed with COVID-19 in a study conducted by NIAID. Lilly is also evaluating its monoclonal antibody candidate that inhibits Angiopoietin 2 (Ang2), LY3127804 in a phase II study in pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome (ARDS). Ang2 is found in high levels in ARDS patients. The study will test if LY3127804 can inhibit the effects of Ang2 and reduce the progression to ARDS or the need for mechanical ventilation in COVID-19 patients
Several other companies are also working on developing new antibodies to combat the disease.
Vir Biotechnology’s (VIR - Free Report) investigational monoclonal antibodies, VIR-7831 and VIR-7832 are expected to directly go to phase II clinical studies sometime in 2020. Regeneron (REGN - Free Report) is developing REGN-COV2, a novel investigational antibody "cocktail" treatment designed to prevent and treat the SARS-CoV-2 virus. Clinical studies are expected to begin this month.
Other than Lilly, larger companies like Pfizer (PFE - Free Report) , Biogen, Glaxo and Amgen also have signed collaborations with smaller biotechs to co-develop antibody therapies/medicines to treat COVID-19.
Lilly currently carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>